John Lu | Chief Executive Officer
HebeCell Corporation

John Lu, Chief Executive Officer, HebeCell Corporation

John Lu , PhD, MPH, is the President and CEO of HebeCell Corporation. focusing on the development of PSC-NK cells for the treatment of human diseases including cancer, autoimmune and viral infection diseases. Before establishing HebeCell, he was the Senior Director of R&D at Advanced Cell technology/Ocata Therapeutics for 11 years. John Has more than 30 years of expereince in stem cell and regenerative medicine as well as >10 year experiences  of cancer research. In an anylysis of global stem cell patent landscape by Nature Biotechnology in 2014, John's patent application and citation ranked number 7 and 5 , respectively. Under John's leadership, HebeCell's properitary ProtoNK cell HC101 has recently been approved by US FDA for phase 1/1b clinical trial for refractory/recurrent Ewing sarcoma patients, which will start patient recrutment soon.

Appearances:



Festival of Biologics Day 2 @ 13:40

The promises and challenges of IPS-derived cell therapies

last published: 18/Nov/26 17:29 GMT

back to speakers

Get involved at Festival of Biologics USA 2027

 

 

TO SPONSOR


Nicholas Matthews

Nicholas.Matthews@terrapinn.com

 

 

TO SPEAK


Jack Beard
Jack.Beard@terrapinn.com

 

MARKETING & PRESS


Ollie McDaid

Ollie.Mcdaid@terrapinn.com

 

Stay Up-to-Date

Join our mailing list to receive exclusive content and offers.

By submitting, you agree to receive email communications from Terrapinn, including upcoming promotions and discounted tickets and news.